New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer

Published:2020-02-17 Issue:3 Volume:146 Page:631-645
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Qiang Huiping,Chang Qing,Xu Jianlin,Qian Jialin,Zhang Yanwei,Lei Yuqiong,Han Baohui,Chu Tianqing^ORCID

Funder

the Western Medicine Guide Project of Shanghai Committee of Science and Technology

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00432-020-03129-6.pdf

Reference75 articles.

1. Baggstrom MQ, Socinski MA, Wang XF et al (2017) Maintenance sunitinib following initial platinum-based combination chemotherapy in advanced-stage IIIB/IV non-small cell lung cancer: a randomized, double-blind, placebo-controlled phase III study-CALGB 30607 (Alliance). J Thorac Oncol 12:843–849. https://doi.org/10.1016/j.jtho.2017.01.022

2. Barlesi F, Scherpereel A, Rittmeyer A et al (2013) Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 31:3004–3011. https://doi.org/10.1200/jco.2012.42.3749

3. Bouzin C, Brouet A, De Vriese J, Dewever J, Feron O (2007) Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J Immunol 178:1505–1511. https://doi.org/10.4049/jimmunol.178.3.1505

4. Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492

5. de Boer RH, Arrieta Ó, Yang CH et al (2011) Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind Phase III trial. J Clin Oncol 29:1067–1074. https://doi.org/10.1200/jco.2010.29.5717

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS);Heliyon;2024-09

2. Antitumor activity of anlotinib in malignant melanoma: modulation of angiogenesis and vasculogenic mimicry;Archives of Dermatological Research;2024-07-03

3. Effectiveness and safety of anlotinib plus anti-programmed cell death 1/ligand 1 (anti-PD-1/PD-L1) antibodies as maintenance therapy after first-line chemotherapy combined with anti-PD-1/PD-L1 antibodies in extensive-stage small cell lung cancer: a real-world study;Journal of Thoracic Disease;2024-07

4. Circ_0060060 Accelerates Metastasis of Non-Small-Cell Lung Carcinoma by Upregulating FUT8;Journal of Biomedical Nanotechnology;2024-07-01

5. A single-center, retrospective study-spring-evaluating the efficacy and safety of recombinant human vascular endothelial inhibitor combined with anti-PD-1 in elderly patients aged 80 and above with NSCLC;Frontiers in Immunology;2024-06-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3